Serological Tests in the Detection of SARS-CoV-2 Antibodies
Authors:
- Kissy Guevara-HoyerKGKissy Guevara-Hoyer
- Jesús Fuentes-AntrásJFJesús Fuentes-Antrás
- Eduardo De la Fuente-MuñozEFEduardo De la Fuente-Muñoz
- Antonia Rodríguez de la PeñaAPAntonia Rodríguez de la Peña
- Marcos ViñuelaMVMarcos Viñuela
- Noemí Cabello-ClotetNCNoemí Cabello-Clotet
- Vicente EstradaVEVicente Estrada
- Esther CulebrasECEsther Culebras
- Alberto Delgado-IribarrenAlberto Delgado-Iribarren
- Mercedes Martínez-NovilloMMMercedes Martínez-Novillo
- Maria José TorrejónMTMaria José Torrejón
- Rebeca Pérez de DiegoRDRebeca Pérez de Diego
Open Access
- 9 April 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (4) , 678
Abstract
Early detection of SARS-CoV-2 is essential for a timely update of health policies and allocation of resources. Particularly, serological testing may allow individuals with low-risk of being contagious of SARS-CoV-2 to return to daily activities. Both private and academic initiatives have sought to develop serological assays to detect anti-SARS-CoV-2 antibodies. Herein, we compared five different assays in active healthcare personnel exposed to SARS-CoV-2 in a large center in Madrid, Spain, in a retrospective study. Median time lapse between polymerase chain-reaction (PCR) and serological testing was 11 days (7–21). All tests assessed IgM/IgG titers except for Euroimmun (IgA/IgG) and The Binding-Site (IgA/IgM/IgG). The highest concordance rate was observed between Dia.Pro and Euroimmun (75.76%), while it was lowest between The Binding-Site and Euroimmun (44.55%). The Binding-Site assay showed the highest concordance (85.52%) with PCR results. Considering PCR results as reference, Dia.Pro was the most sensitive test, although The Binding-Site assay exhibited the highest area under the curve (AUC; 0.85). OrientGene and MAGLUMI tests were performed in a smaller cohort with confirmed infection and thus were not adequate to estimate sensitivity and specificity. The Binding-Site assay presented the best joint sensitivity and specificity among all the tests analyzed in our cohort. Likewise, this serological assay presents a greater repertoire of antibodies and antigen-regions tested, which is why each individual’s humoral immunity is more accurately reflected. The better the immunity test, the most adequate the health strategy to take in terms of organization of consultations, surgery, and treatments in vulnerable patients. The three antibody classes (IgG/IgM/IgA) were determined jointly, which translates to an economic impact on healthcare. While their role in the protection status remains elusive, serological tests add a valuable tool in the early management of SARS-CoV-2 after known exposition.Keywords
Funding Information
- CRISCancer Foundation (SSR.C01CRIS)
This publication has 31 references indexed in Scilit:
- Profile of specific antibodies to SARS-CoV-2: The first reportJournal of Infection, 2020
- Laboratory Diagnosis of COVID-19: Current Issues and ChallengesJournal of Clinical Microbiology, 2020
- Viral load of SARS-CoV-2 in clinical samplesThe Lancet Infectious Diseases, 2020
- SARS-CoV-2 specific antibody responses in COVID-19 patientsmedRxiv, 2020
- Secondary attack rate and superspreading events for SARS-CoV-2The Lancet, 2020
- The progress of 2019 novel coronavirus event in ChinaJournal of Medical Virology, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Origin and evolution of pathogenic coronavirusesNature Reviews Microbiology, 2018
- Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virusJournal of Clinical Virology, 2009
- Identification of an epitope of SARS-coronavirus nucleocapsid proteinCell Research, 2003